Patents Examined by John Lucas
  • Patent number: 5747332
    Abstract: A method for purifying heat shock protein complexes is provided which comprises the steps of adding a solution containing heat shock protein complexes, in which heat shock proteins are associated with peptides, polypeptides, denatured proteins or antigens, to a column containing an ADP matrix to bind the heat shock proteins complexes to the ADP matrix and adding a buffer containing ADP to the column to remove the heat shock protein complexes in an elution product. Additionally a method for synthesizing heat shock protein complexes and purifying the complexes so produced is provided which comprises the steps of adding heat shock proteins to an ADP matrix column to bind them to the matrix, adding a solution of peptides, polypeptides, denatured proteins or antigens to the column to bind them to the heat shock proteins as heat shock protein complexes and adding a buffer containing ADP to the column to remove the complexes in an elution product.
    Type: Grant
    Filed: September 20, 1996
    Date of Patent: May 5, 1998
    Assignee: University of New Mexico
    Inventors: Erik S. Wallen, Jan Roigas, Pope L. Moseley
  • Patent number: 5723125
    Abstract: Disclosed is a hybrid recombinant protein consisting of human interferon, preferably interferon-.alpha. (IFN.alpha.), and human immunoglobulin Fc fragment, preferably .gamma.4 chain, joined by a peptide linker comprising the sequence Gly Gly Ser Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser (SEQ ID NO:1).
    Type: Grant
    Filed: September 25, 1996
    Date of Patent: March 3, 1998
    Assignee: Tanox Biosystems, Inc.
    Inventors: Tse Wen Chang, Liming Yu
  • Patent number: 5721353
    Abstract: A novel motilin analog peptide containing leucine instead of the usual 13th amino acid methionine, as in the naturally occurring motilin, is produced by gene recombination techniques in which several or identical genes, each coding for the novel peptide, are joined in series into a vector. The resultant recombinant DNA is introduced into Escherichia coli and the resultant transformant is cultivated. The resulting polymeric peptide can be cleaved to give the desired peptide.
    Type: Grant
    Filed: February 13, 1995
    Date of Patent: February 24, 1998
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Shinkichi Honda, Tatsunari Nishi, Seiga Itoh, Moriyuki Sato
  • Patent number: 5714148
    Abstract: Prodrugs, of generic formula I, are disclosed for use in antibody directed enzyme prodrug therapy (ADEPT). The prodrugs are substrates for carboxypeptidase G2 (CPG2) and yield more active cytotoxic drugs than known products of CPG2 catalysed reactions.
    Type: Grant
    Filed: September 30, 1996
    Date of Patent: February 3, 1998
    Assignees: Zeneca Limited, Cancer Research Campaign Technology Limited
    Inventors: Philip John Burke, Robert Ian Dowell, Anthony Brian Mauger, Caroline Joy Springer
  • Patent number: 5714350
    Abstract: The present invention provides methods for producing mutationally-altered immunoglobulins and compositions containing such mutationally-altered immunoglobulins, wherein the mutationally-altered immunoglobulins have at least one mutation that alters the pattern of glycosylation in a variable region and thereby modifies the affinity of the immunoglobulin for a preselected antigen. The methods and compositions of the invention provide immunoglobulins that possess increased affinity for antigen. Such glycosylation-altered immunoglobulins are suitable for diagnostic and therapeutic applications.
    Type: Grant
    Filed: January 13, 1995
    Date of Patent: February 3, 1998
    Assignees: Protein Design Labs, Inc., Sloan-Kettering Cancer Center
    Inventors: Man Sung Co, David A. Scheinberg, Cary L. Queen
  • Patent number: 5712120
    Abstract: Modified chimaeric antibodies, and antibody heavy and light chains, which comprise variable domains derived from a first mammalian species, usually mouse, and constant domains from a second mammalian species, usually human. Modification concerns the variable domains, in particular the framework regions of the variable domains. The modifications are made only in T-cell antigenic structures present in framework regions, and do not cover canonical structures or Vernier zone. The modifications adapt the amino acid sequences concerned to those occurring in corresponding antibodies derived from said second mammalian species. Thus, the modified chimaeric antibodies retain the original antigen recognition and binding properties but become less immunogenic to said second mammalian species, which improves their therapeutical utility with said second mammalian species. Recombinant DNA technology may be used to construct and produce the modified chimaeric antibodies.
    Type: Grant
    Filed: June 30, 1995
    Date of Patent: January 27, 1998
    Assignee: Centro De Immunologia Molecular
    Inventors: Rolando Perez Rodriguez, Christina Maria Mateo de Acosta del Rio, Josefa Lombardero Valladares
  • Patent number: 5705154
    Abstract: Humanized monoclonal antibodies are provided which are specific for human IL-4 and have properties unexpectedly superior to other, previously available humanized antibodies. Single-chain binding proteins, fusion proteins, and antigenic or IL-4 binding fragments of such antibodies are also provided by this invention. Also provided are nucleic acids which encode the heavy and light chain variable regions of such monoclonal antibodies or antigenic fragments thereof; anti-idiotypic antibodies; and methods for detecting, measuring and immunopurifying human IL-4, and for blocking or mimicking the biological activity of human IL-4.
    Type: Grant
    Filed: September 6, 1996
    Date of Patent: January 6, 1998
    Assignee: Schering Corporation
    Inventors: Barbara Dalie, Kenneth Miller, Nicholas Murgolo, Stephen Tindall
  • Patent number: 5703048
    Abstract: The present invention provides methods for preventing occurrence or progression of liver damage using hepatocyte growth factor. In the methods, a preventatively effective amount of the hepatocyte growth factor is administered to the patient. The hepatocyte growth factor can be administered, for instance, prior to administering a hepatotoxic therapy to the patient. The hepatocyte growth factor can further be administered with activin or transforming growth factor-beta to prevent liver damage. Compositions comprising hepatocyte growth factor and activin antagonist or transforming growth factor-beta antagonist are also provided by the invention.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: December 30, 1997
    Assignee: Genentech, Inc,
    Inventors: Filip Roos, Ralph Schwall
  • Patent number: 5698195
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-.alpha. (TNF.alpha.) and are useful in vivo for diagnosis and therapy of a number of TNF.alpha.-mediated pathologies and conditions, including rheumatoid arthritis as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: October 18, 1994
    Date of Patent: December 16, 1997
    Assignees: New York University Medical Center, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Patent number: 5690935
    Abstract: Cytotoxic biotherapeutic agents effective for treating certain types of cancer in humans are provided which comprise the TP-3 murine monoclonal antibody chemically conjugated to pokeweed antiviral protein (PAP). The invention further provides a method which utilizes the disclosed cytotoxic biotherapeutic agents to systemically treat cancer patients. With slight modifications the method of the present invention should be generally applicable to preparation and use of other cytotoxic biotherapeutic agents using chemical or recombinant derivatives of the TP-3 or TP-1 antibodies or PAP toxin. The invention is applicable to cancer patients who express the p80 antigen recognized by the TP-1/TP-3 antibodies either on the surface of their tumor cells or on the tumor blood vessels.
    Type: Grant
    Filed: January 13, 1995
    Date of Patent: November 25, 1997
    Assignee: Regents of the University of Minnesota
    Inventors: Fatih M. Uckun, Peter M. Anderson
  • Patent number: 5686249
    Abstract: A method of determining frost hardiness of a conifer seedling, which comprises detecting an amount of a cold protein in tissue of said conifer, the cold protein being a protein of approximately 19 kD that increase significantly in amount in the conifer during fall season (autumnal) months and that imparts frost hardiness to the seedling, and then assessing frost hardiness based on said detected amount. In the case of Pinus lambertiana, the cold protein includes the N-terminal sequence: Val--Ser--Gly--Thr--Ser--Ser--Thr--Glu--Glu--Val--Val--Gln--Asn--Glu--Ala- -Arg--Arg--Leu--Trp--Asn ?SEQ ID NO:1!; and in the case of Pinus monticola, the cold protein includes the N-terminal sequence: Val--Ser--Gly--Thr--Ser--Ser--Thr--Glu--Glu--Val--Val--Gln--Val--Glu--Ala- -Arg--Arg--Leu--Trp--Asn--Ala--Thr--Thr--Lys--Asp ?SEQ ID NO:3!. The invention also relates to conjugates and antibodies used in the method.
    Type: Grant
    Filed: November 9, 1994
    Date of Patent: November 11, 1997
    Assignee: Forestry Canada
    Inventor: Abul K. M. Ekramoddoullah
  • Patent number: 5679548
    Abstract: The present invention describes methods for producing metal binding sites on polypeptides, and particularly for producing metal binding sites within the CDR regions of immunoglobulin heavy or light chains that are displayed on the surface of filamentous phage particles. The invention also describes oligonucleotides useful for preparing the metal binding sites, and human monoclonal antibodies produced by the present methods.
    Type: Grant
    Filed: June 14, 1993
    Date of Patent: October 21, 1997
    Assignee: The Scripps Research Institute
    Inventors: Carlos F. Barbas, Jonathan Rosenblum, Richard A. Lerner
  • Patent number: 5667978
    Abstract: The present invention provides an anti-N-CAM monoclonal antibody which enhances, rather than inhibits, neurite outgrowth both in vitro and in vivo. The antibody has positive regulatory effects on nerve cells of both the central and peripheral nervous systems, and is useful for enhancing neurite outgrowth in in vitro studies and for improving nerve regeneration and repair in vivo.
    Type: Grant
    Filed: May 3, 1996
    Date of Patent: September 16, 1997
    Assignee: Becton, Dickinson and Company
    Inventors: Duane David Bronson, John Jacob Hemperly
  • Patent number: 5658568
    Abstract: A compound comprises a target cell-specific portion, such as an antibody specific to tumour cell antigens, and an inactivating portion, such as an enzyme, capable of converting a substance which in its native state is able to inhibit the effect of a cytotoxic agent into a substance which has less effect against said cytotoxic agent. The prolonged action of a cytotoxic agent at tumour sites is therefore possible whilst protecting normal tissues from the effects of the cytotoxic agent.
    Type: Grant
    Filed: July 8, 1994
    Date of Patent: August 19, 1997
    Assignee: AEPACT Limited
    Inventor: Kenneth Dawson Bagshawe
  • Patent number: 5656272
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-.alpha. (TNF.alpha.) and are useful in vivo for diagnosis and therapy of a number of TNF.alpha.-mediated pathologies and conditions, including Crohn's disease, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: February 4, 1994
    Date of Patent: August 12, 1997
    Assignees: New York University Medical Center, Centocor, Inc.
    Inventors: Junming Le, Jan Vilcek, Peter Dadonna, John Ghrayeb, David Knight, Scott A. Siegel
  • Patent number: 5654404
    Abstract: The present invention provides methods for preventing occurrence or progression of liver damage using hepatocyte growth factor. In the methods, a preventatively effective amount of the hepatocyte growth factor is administered to the patient. The hepatocyte growth factor can be administered, for instance, prior to administering a hepatotoxic therapy to the patient. The hepatocyte growth factor can further be administered with activin or transforming growth factor-beta to prevent liver damage. Compositions comprising hepatocyte growth factor and activin antagonist or transforming growth factor-beta antagonist are also provided by the invention.
    Type: Grant
    Filed: April 10, 1995
    Date of Patent: August 5, 1997
    Assignee: Genentech, Inc.
    Inventors: Filip Roos, Ralph Schwall
  • Patent number: 5653979
    Abstract: A multimolecular complex made up of a plasminogen activator conjugated to anti-ACE Mab 9B9 capable of delivering the plasminogen activator to the pulmonary endothelium is provided. Methods of using this complex to selectively deliver the plasminogen activator to the pulmonary endothelium to enhance fibrinolysis in the lungs of an animal are also provided. In addition, a method of prolonging the time a plasminogen activator is present in the circulation of an animal by conjugating the plasminogen activator to anti-ACE Mab 9B9 is also provided.
    Type: Grant
    Filed: March 30, 1995
    Date of Patent: August 5, 1997
    Assignee: Trustees of the University of Pennsylvania
    Inventors: Vladimir R. Muzykantov, Elliot S. Barnathan
  • Patent number: 5653980
    Abstract: The invention relates to a vaccine, preferably for human use, against IgE-mediated allergic reactions. The vaccine contains a protein having the entire amino acid sequence of the constant CH2-CH3 domains of the epsilon chain of the IgE molecule or a structurally stable unit of said amino acid sequence, the protein optionally being coupled to one or more heterologous carrier proteins, and optionally containing an adjuvant. The vaccine is injected, with or without adjuvant, to raise the concentration of endogenous anti-IgE antibodies in the plasma of allergy subjects. In practice, the vaccine can be used against all types of IgE-mediated allergies since the antibodies are not dependent of the antigen specificity of the IgE molecule but will reduce the total IgE pool of the subject. Therefore, the vaccine is aimed at being used for treatment of subjects having different types of IgE-mediated allergies.
    Type: Grant
    Filed: March 23, 1994
    Date of Patent: August 5, 1997
    Inventor: Lars T. Hellman
  • Patent number: 5651969
    Abstract: The present invention provides an anti-N-CAM monoclonal antibody which enhances, rather than inhibits, neurite outgrowth both in vitro and in vivo. The antibody has positive regulatory effects on nerve cells of both the central and peripheral nervous systems, and is useful for enhancing neurite outgrowth in in vitro studies and for improving nerve regeneration and repair in vivo.
    Type: Grant
    Filed: May 3, 1996
    Date of Patent: July 29, 1997
    Assignee: Becton, Dickinson and Company
    Inventors: Duane David Bronson, John Jacob Hemperly
  • Patent number: 5650284
    Abstract: The subject invention provides an antibody which specifically binds to the product of a reaction between a labeling substance and a substrate. The subject invention also provides a method of making an immunogen used to produce the antibody of the subject invention. The invention further provides methods of using the subject antibody for detecting an antigen of interest in a sample, for example detecting a protein comprising an amino acid sequence of interest and detecting a nucleic acid molecule comprising a nucleic acid sequence of interest.
    Type: Grant
    Filed: March 14, 1995
    Date of Patent: July 22, 1997
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Bernard F. Erlanger, Bi-Xing Chen